It seems the losing streak continues for the Canadian Cannabis LP Index for the sixth month now, after declining 13.5% in December to 194.95, New Cannabis Ventures writes.
After a 1% gain in June, the index retreated nearly 27% in the third quarter.
The index, which fell 30.1% in 2020 to end at 275.16, dropped 26% in the fourth quarter and 29.2% for all of 2021.
In addition, it remains considerably below the all-time closing high of 1314.33 in September 2018. A new multi-year closing low of 196.10 was recorded in March 2020.
The index includes 25 qualifying publicly traded cannabis companies that traded in Canada at the end of October. The companies are divided into three sub-indexes, including Canadian Cannabis LP Tier 1 Index (5 companies), Canadian Cannabis LP Tier 2 Index (8 companies) and Canadian Cannabis LP Tier 3 Index (12 companies).
The index, rebalanced each month, requires companies to have a price of at least CA$0.20 ($0.16) unless they are generating at least CA$2.5 million quarterly from their cannabis production operations.
The overall index will have 24 constituents for January, as Village Farms has delisted from the TSX.
Tier 1
The worst performer among the largest Canadian LPs was HEXO, declining 38%, followed by Tilray's decline of 31%.
Tier 2
After losing 35.9% in 2020, the Canadian Cannabis LP Tier 2 Index closed at 365.19, only to continue dropping by 2.5% in 2021. In December, Tier 2 fell 15% to 302.79.
The Canadian producer of cannabis edibles, Indiva, revealed a 143% year-over-year spike in gross revenue recently reaching CA$8.3 million in the third quarter, which was the company's 7th consecutive quarter of year-over-year net revenue growth.
Tier 3
Tier 3, which included the 12 qualifying LPs that report cannabis-related quarterly sales of CA$2.5-CA$7.5 million rose 0.4% as it closed at 53.35. After ending at 66.59 in 2020, it was down 19.9% in 2021.
Lifeist Wellness recently announced the launch of CELLF, a novel cellular therapeutic compound targeting systemic fatigue, via its biosciences and consumer wellness subsidiary, Mikra Cellular Sciences Inc.
Photo: Courtesy of Maxim Hopman on Unsplash
© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
To add Benzinga News as your preferred source on Google, click here.
